Literature DB >> 16517725

Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain.

James F Curtin1, Gwendalyn D King, Carlos Barcia, Chunyan Liu, François X Hubert, Carole Guillonneau, Régis Josien, Ignacio Anegon, Pedro R Lowenstein, Maria G Castro.   

Abstract

The lack of professional afferent APCs in naive brain parenchyma contributes to the systemic immune ignorance to Ags localized exclusively within the brain. Dendritic cells (DCs) appear within the brain as a consequence of inflammation, but no molecular mechanisms accounting for this influx have been described. In this study we demonstrate that Fms-like tyrosine kinase 3 ligand (Flt3L) recruits plasmacytoid DCs (pDCs; >50-fold; p < 0.001) to the brain parenchyma. These pDCs expressed IFN-alpha, the hallmark cytokine produced by pDCs, indicating recruitment and activation in situ of bona fide pDCs within the brain parenchyma. Flt3L did not increase the numbers of conventional DCs, macrophages, or B, T, NK, NKT, or microglial cells within the brain. Our data demonstrate that Flt3L reconstitutes a crucial afferent component of the immune response, namely, professional APCs within the brain parenchyma, and this could counteract the intrinsic systemic immune ignorance to Ags localized exclusively within the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517725      PMCID: PMC1592227          DOI: 10.4049/jimmunol.176.6.3566

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

Authors:  Melanie Greter; Frank L Heppner; Maria P Lemos; Bernhard M Odermatt; Norbert Goebels; Terri Laufer; Randolph J Noelle; Burkhard Becher
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

Review 3.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.

Authors:  Yong-Jun Liu
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  Cultured human adult microglia from different donors display stable cytokine, chemokine and growth factor gene profiles but respond differently to a pro-inflammatory stimulus.

Authors:  Sonja Meeuwsen; Malika Bsibsi; Carla Persoon-Deen; Rivka Ravid; Johannes M van Noort
Journal:  Neuroimmunomodulation       Date:  2005       Impact factor: 2.492

5.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials.

Authors:  R A Dewey; G Morrissey; C M Cowsill; D Stone; F Bolognani; N J Dodd; T D Southgate; D Klatzmann; H Lassmann; M G Castro; P R Löwenstein
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

6.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Authors:  Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-04       Impact factor: 11.205

7.  Migration of dendritic cells into the brain in a mouse model of prion disease.

Authors:  Barbara Rosicarelli; Barbara Serafini; Marco Sbriccoli; Mei Lu; Franco Cardone; Maurizio Pocchiari; Francesca Aloisi
Journal:  J Neuroimmunol       Date:  2005-08       Impact factor: 3.478

8.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

9.  Blood-derived dendritic cells in an acute brain injury.

Authors:  Tracey A Newman; Ian Galea; Nico van Rooijen; V Hugh Perry
Journal:  J Neuroimmunol       Date:  2005-09       Impact factor: 3.478

Review 10.  Production of type I interferons: plasmacytoid dendritic cells and beyond.

Authors:  Carine Asselin-Paturel; Giorgio Trinchieri
Journal:  J Exp Med       Date:  2005-08-15       Impact factor: 14.307

View more
  50 in total

1.  Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Authors:  Yohei Mineharu; Gwendalyn D King; A K M G Muhammad; Serguei Bannykh; Kurt M Kroeger; Chunyan Liu; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.

Authors:  Benjamin D Clarkson; Erika Héninger; Melissa G Harris; JangEun Lee; Matyas Sandor; Zsuzsanna Fabry
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.

Authors:  Latt Latt Aung; Andrew Brooks; Steven A Greenberg; Michael L Rosenberg; Suhayl Dhib-Jalbut; Konstantin E Balashov
Journal:  J Neuroimmunol       Date:  2012-06-09       Impact factor: 3.478

4.  Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.

Authors:  Daniel Larocque; Nicholas S R Sanderson; Josée Bergeron; James F Curtin; Joe Girton; Mia Wibowo; Niyati Bondale; Kurt M Kroeger; Jieping Yang; Liliana M Lacayo; Kevin C Reyes; Catherine Farrokhi; Robert N Pechnick; Maria G Castro; Pedro R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

5.  Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Authors:  Gregory J Baker; Maria G Castro; Pedro R Lowenstein
Journal:  J Vis Exp       Date:  2015-11-28       Impact factor: 1.355

Review 6.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

Review 7.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

Review 8.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

9.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

10.  Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis.

Authors:  Mario Skarica; Tianhong Wang; Erin McCadden; David Kardian; Peter A Calabresi; Donald Small; Katharine A Whartenby
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.